Increased HIV screening may help identify more people with the disease, but there may not be enough resources to provide them with the care they need. The Institute of Medicine's Committee on HIV Screening and Access to Care concludes that more practitioners must be trained in HIV/AIDS care and treatment and their hospitals, clinics, and health departments must receive sufficient funding to meet a growing demand for care.
Thousands of HIV-positive women give birth every year. Further, because many pregnant women are not tested for HIV and therefore do not receive treatment, the number of children born with HIV is still unacceptably high. What can we do to eliminate this tragic and costly inheritance? In response to a congressional request, this book evaluates the extent to which state efforts have been effective in reducing the perinatal transmission of HIV. The committee recommends that testing HIV be a routine part of prenatal care, and that health care providers notify women that HIV testing is part of the usual array of prenatal tests and that they have an opportunity to refuse the HIV test. This approach could help both reduce the number of pediatric AIDS cases and improve treatment for mothers with AIDS. Reducing the Odds will be of special interest to federal, state, and local health policymakers, prenatal care providers, maternal and child health specialists, public health practitioners, and advocates for HIV/AIDS patients. January
There hasn't been a resource to inform readers about the HIV risk confronting our adolescent population--until now! In Adolescents and AIDS, leading researchers in health, medicine, sociology, and psychology describe the risks to this vulnerable population. Divided into three parts (epidemiology, prevention/risk reduction, and policy), this comprehensive book addresses not only adolescents in general, but includes specific chapters on high-risk populations such as minority, incarcerated and homeless youth. The authors explore the data and theoretical underpinnings necessary for designing and implementing effective risk-reduction and prevention programs by approaching the AIDS epidemic as a social and developmental crisis that adolescents are ill-prepared to address. While proposing appropriate theoretical models for behavior change, the book also evaluates the effectiveness of various intervention strategies ranging from school-based programs to mass-media approaches and offers public policy recommendations for intervening for this population. Health professionals, researchers, policy analysts, clinicians, counselors, and students will find this timely text a valuable resource.
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
In 1979, Dr. Allan Ronald, a specialist in infectious diseases from Canada, and Dr. Herbert Nsanze, head of medical microbiology at University of Nairobi, met through the World Health Organization. Ronald had just completed a successful project that cured a chancroid (genital ulcer) epidemic in Winnipeg and Nsanze asked him to come to Kenya to help with Kenya’s “sexual diseases problem.” That initial invitation led to a groundbreaking international scientific collaboration that would uncover critical pieces in the complex puzzle that became today’s HIV/AIDS pandemic. In Piecing the Puzzle, journalist and documentary filmmaker Larry Krotz chronicles the fascinating history of the pioneering Kenyan, Canadian, Belgian, and American research team that uncovered HIV/AIDS in Kenya, their scientific breakthroughs and setbacks, and their exceptional thirty-year relationship that began a new era of global health collaboration.
Viral Infections and Antiviral Therapies provides comprehensive coverage of viral infections and their transmission. Coverage includes antiviral agents, therapeutics, their mechanisms and treatment strategies. The book is organized into four sections, including an introduction to antiviral therapies, viral infections and their transmission, antiviral agents and therapeutics, and a market overview and future developments. The chapters in each section of the book discuss various key topics that are contributed to by an international group of leading experts. - Covers emerging and sexually transmitted viruses, including mode of transmission and pathophysiology of viral infections - Describes antiviral agents and therapeutics for viruses such as rotaviruses, enteroviruses and coronaviruses - Discusses strategies for the delivery of antiviral agents and vaccinations
